Presentation of our society Since 1991, our society promotes medical practice guidelines for the prevention of cardiovascular diseases in Belgium as well as scientific and clinical research in the field of hyperlipidemic pathologies. Our society is the official Belgian representative of the European Atherosclerosis Society (EAS) and the International …Alexandros D. Tselepis was born in 1954 in Heraklion Crete, Greece. He has graduated in Pharmacy from the School of Pharmacy, University of Thessaloniki and in Medicine from the Medical School, University of Ioannina, Greece. He obtained his PhD in Clinical Biochemistry in 1986 from the University of Ioannina, Greece. Despite possible atherogenicity of marked elevations in circulating levels of plant sterols/stanols, protective effects have been observed in some animal models of atherosclerosis. Higher plasma levels of plant sterols/stanols associated with intakes of 2 g/day in man have not been linked to adverse effects on health in long-term human studies. European Atherosclerosis Society | 3196 seguidores en LinkedIn. Advancing and exchanging knowledge of the causes, natural history, treatments and prevention of atherosclerotic disease. | For more than 50 years the Society’s expertise has been used to teach clinicians how to manage lipid disorders and how to prevent atherosclerosis. …Atherosclerosis particularly welcomes original or review papers regarding the pathogenesis, the environmental, genetic, and epigenetic basis, and the diagnosis, treatment, and risk factors of atherosclerosis and related diseases. Complimentary online access is available to all members of the European Atherosclerosis Society.Elevated levels of low-density lipoprotein cholesterol (LDL-C) are associated with increased risk of coronary heart disease and stroke. Guidelines for the management of dyslipidaemia from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) were updated in late 2019 in light of recent intervention trials involving the …More recently, in September 2019, the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) published a new guideline and introduced updated recommendations, including recommending that LDL-C be lowered as much as possible, specifically a goal of <1.4 mmol/L (<55 mg/dL) in patients with VHR, including …Student**. € 50. € 75. € 100. Note: * To be eligible to register at EAS member registration fee for the EAS 2023 Mannheim, you must have paid your EAS individual membership fee for 2022 to the Society. If your EAS membership fee for 2022 has not been paid by the end of the year, the non-member registration fee will apply at the EAS 2023 ...To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the …EAS Certificate of Excellence in Lipidology 2023 Update (ELM23-A00075) has been accredited by the EACCME®, the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. Each medical specialist should claim only those credits that he/she actually spent in the ... Background: The Consensus Statement from the European Atherosclerosis Society (EAS) Consensus Panel 2017 concludes on the basis of 3 different types of clinical studies that low-density lipoprotein (LDL) causes atherosclerotic cardiovascular disease (ASCVD). In Mendelian randomization studies, rare genetic mutations affecting LDL receptor ... Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in …This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, provides clinical guidance for testing and treating elevated Lp(a) levels, and considers its inclusion in global risk estimation. …28 European Atherosclerosis Society, Gothenburg, Sweden. 29 Department of Medicine, Columbia University College of Physicians and Surgeons, New York, USA. 30 National Institute for Health and Medical Research (INSERM), and University of Pierre and Marie Curie-Paris 6, Pitié Salpêtrière, Paris, France.26 European Atherosclerosis Society, Mässans Gata 10, Gothenburg SE-412 51, Sweden. 27 Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano and IRCCS MultiMedica, Via Festa del Perdono 7, Milan 20122, Italy.Memo. On behalf of the European Atherosclerosis Society (EAS) and the German societies DACH, DGFF and DGAF we are proud to invite you to participate in the 91st EAS Congress in the city of Mannheim. Mannheim is conveniently located in southern Germany with close access to Frankfurt and is home to inventions such as the …Aug 23, 2023 · This European Atherosclerosis Society (EAS) position statement is a ‘call to action’ for improving ASCVD prevention strategies in women, with a focus on sex differences in lipids over the life course. Apr 28, 2023 · In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. One of the novelties of this statement is a new risk calculator showing how Lp(a) influences lifetime risk for ASCVD and that global risk may be ... The 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines for the management of dyslipidemias support the evaluation and consideration of non-HDL-C and apoB as secondary targets for lipid control . Non-HDL cholesterol is highly correlated with apoB levels but is not always consistent.28 European Atherosclerosis Society, Gothenburg, Sweden. 29 Department of Medicine, Columbia University College of Physicians and Surgeons, New York, USA. 30 National Institute for Health and Medical Research (INSERM), and University of Pierre and Marie Curie-Paris 6, Pitié Salpêtrière, Paris, France. PMID: 29718253 …Based on evidence from large-scale population studies and registries and on consensus of expert opinions, the European Atherosclerosis Society/European Federation of Clinical Chemistry and Laboratory Medicine (EAS/EFLM) joint consensus statement proposes recommendations on (i) situations when fasting is not required for a …EAS Certificate of Excellence in Lipidology (2021 Update) (ELM19-A00022) has been accredited by the EACCME®, the European Accreditation Council for Continuing Medical Education ... European Atherosclerosis Society Första Långgatan 4A 413 03 Göteborg Sweden. Phone: +46 (0) 31 760 24 27. Organisation number: 802418-0427.† See European Atherosclerosis Society Consensus Panel members given in Appendix Section. &The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ... Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe Atherosclerosis . 2021 Apr:322:77-81. doi: 10.1016/j.atherosclerosis.2021.02.007. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory MedicineIn 2020, we celebrated two anniversaries of our journal at the Annual European Atherosclerosis Society (EAS) Congress. The first issues were published in 1960, however, by the name “Journal of Atherosclerosis”. Ten years later, the journal was renamed “Atherosclerosis”. Since then, nearly 12,000 original articles and 700 review …Latest Newsletter by the European Atherosclerosis Society. 4 Φεβρουαρίου 2021, 10:44. Merry Healthier Christmas. 23 Δεκεμβρίου 2020, 08:41. Περισσότερα .The European Atherosclerosis Journal is an official journal of SITeCS (Italian Society for Experimental and Clinical Therapeutics). The European Atherosclerosis Journal is a new international, peer-reviewed, fully open access, four-monthly journal covering all topics within atherosclerosis and cardiovascular disease …Mar 27, 2021 · ], the European Atherosclerosis Society (EAS) reaffirmed its commitment to the 2030 Agenda Goals, in particular Sustainable Development Goal 3, which targets at least 30% reduction in premature mortality due to noncommunicable disease (NCD) by 2030. More recently, in September 2019, the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) published a new guideline and introduced updated recommendations, including recommending that LDL-C be lowered as much as possible, specifically a goal of <1.4 mmol/L (<55 mg/dL) in patients with VHR, including …In 2014, the European Atherosclerosis Society (EAS) statement on homozygous familial hypercholesterolaemia (HoFH) 1 focused attention on this rare and life-threatening disease, characterized by markedly elevated plasma low-density lipoprotein cholesterol (LDL-C) levels from birth and accelerated atherosclerotic cardiovascular …This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of …Evidence from international cohort studies has shown increased coronary atherosclerosis in male athletes vs controls,1 whereas data for female …The tutorial builds on earlier work done by the European Atherosclerosis Society, addressing the important role of diet and lifestyle which form the basis for dyslipidaemia treatment and CVD prevention. The tutorial includes chapters on CVD risk factors, diet and lifestyle interventions, the role of dietary fats, dietary fibres, foods with added plant … On behalf of the European Atherosclerosis Society (EAS) and the German societies DACH, DGFF and DGAF we are proud to invite you to participate in the 91st EAS Congress in the city of Mannheim. Mannheim is conveniently located in southern Germany with close access to Frankfurt and is home to inventions such as the automobile, bicycle and tractor. The FH Studies Collaboration. Familial Hypercholesterolaemia (FH) represents a major global health problem because, despite being very common, it is widely underdiagnosed, undertreated and, as a result often fatal. The consequences of FH in the form of premature atherosclerosis and cardiovascular events are potentially preventable, but require ...Read our publications. Latest from the FHSC registry: take action now for universal cholesterol screening in early life. Publications, Commentaries. EAS issues ‘call-to-action’ statement on women, lipids, and atherosclerotic cardiovascular disease. Publications, Commentaries. Update to consensus statement on homozygous familial ...Dec 12, 2021 · L.S.T. is a Past-President, the European Atherosclerosis Society (EAS) and an Editorial Board Member, The European Heart Journal. Data availability The data underlying this article will be shared on reasonable request to the corresponding author. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. More than a decade after first highlighting lipoprotein(a) [Lp(a)] (1), the European Atherosclerosis Society (EAS) has published an updated consensus statement (2).This 2022 statement brings together extensive evidence for elevated Lp(a) concentration as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) (3), irrespective of …Further information can be found in the Consensus Statement of the European Atherosclerosis Society [7]. A systematic review found that the incidence of drug-induced hepatotoxicity in patients taking statins is unknown [8], but it is recommended to have the liver enzymes (alanine transaminase - ALT) checked every 8–12 weeks after a statin …Apr 28, 2023 · In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. One of the novelties of this statement is a new risk calculator showing how Lp(a) influences lifetime risk for ASCVD and that global risk may be ... The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory diagnostics of atherogenic lipoproteins. Total cholesterol (TC), triglycerides ( …Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38:2459–2472. [PMC free article] [Google Scholar]Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory MedicineIn 2014, the European Atherosclerosis Society (EAS) statement on homozygous familial hypercholesterolaemia (HoFH) 1 focused attention on this rare and life-threatening disease, characterized by markedly elevated plasma low-density lipoprotein cholesterol (LDL-C) levels from birth and accelerated atherosclerotic cardiovascular …A consensus statement by the European Atherosclerosis Society on the role of Lp (a) in ASCVD and AVS, its association with cardiovascular …Jun 21, 2020 · How do low-density lipoproteins cause atherosclerotic cardiovascular disease? Find out the latest pathophysiological, genetic, and therapeutic insights from a consensus statement by the European Atherosclerosis Society Consensus Panel. This comprehensive review summarizes the evidence from various studies and provides recommendations for clinical practice. Aug 27, 2016 · These updated 2016 guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. The guidance includes sections on: the evaluation of laboratory lipid and apolipoprotein parameters; treatment targets; lifestyle modifications to improve the plasma lipid profile; drugs for treatment of ... About EAS Congress. EAS organises a 4-day scientific Congress in a different European city each year – scientific meetings bringing together over 2,000 basic …Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217:3-46. Ros E. Health benefits of nut consumption. Nutrients …The EAS Familial Hypercholesterolemia Studies Collaboration (FHSC) is a worldwide initiative supported by the European Atherosclerosis Society (EAS) that brings …This review summarizes the main provisions of the new, issued in 2016, recommendations of the European Society of Cardiology and Atherosclerosis Society in cooperation with the European Association on Cardiovascular Prevention and Rehabilitation on Cardiovascular disease prevention and Management of dyslipidemia.Introduction. Atherosclerotic cardiovascular disease (ASCVD) starts early, even in childhood. 1 , 2 Non-invasive imaging in the PESA (Progression of Early Subclinical Atherosclerosis) study revealed that 71% and 43% of middle-aged men and women, respectively, have evidence of subclinical atherosclerosis. 3 Extensive evidence from …The FH Studies Collaboration. Familial Hypercholesterolaemia (FH) represents a major global health problem because, despite being very common, it is widely underdiagnosed, undertreated and, as a result often fatal. The consequences of FH in the form of premature atherosclerosis and cardiovascular events are potentially preventable, but require ...This consensus statement from the European Atherosclerosis Society (EAS) task force aims to address these uncertainties by providing a theoretical background to the underlying pathophysiology, and practical clinical guidance, for rare lipoprotein disorders associated with extreme concentrations (either low or high) of LDL cholesterol, triglycerides, and …The tutorial builds on earlier work done by the European Atherosclerosis Society, addressing the important role of diet and lifestyle which form the basis for dyslipidaemia treatment and CVD prevention. The tutorial includes chapters on CVD risk factors, diet and lifestyle interventions, the role of dietary fats, dietary fibres, foods with added plant …Background and aims: This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients. Methods: Evidence-based review. Results: Statin-ezetimibe combination treatment is the first …Alexandros D. Tselepis was born in 1954 in Heraklion Crete, Greece. He has graduated in Pharmacy from the School of Pharmacy, University of Thessaloniki and in Medicine from the Medical School, University of Ioannina, Greece. He obtained his PhD in Clinical Biochemistry in 1986 from the University of Ioannina, Greece.The FH Studies Collaboration. Familial Hypercholesterolaemia (FH) represents a major global health problem because, despite being very common, it is widely underdiagnosed, undertreated and, as a result often fatal. The consequences of FH in the form of premature atherosclerosis and cardiovascular events are potentially preventable, but require ...MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the …Dec 12, 2021 · L.S.T. is a Past-President, the European Atherosclerosis Society (EAS) and an Editorial Board Member, The European Heart Journal. Data availability The data underlying this article will be shared on reasonable request to the corresponding author. EAS 2025 – European Atherosclerosis Society. Congress Dates: May 3 – 7, 2025. Congress Venue: Glasgow, United Kingdom . About the Congress: During the meeting we will explore the latest developments in basic, translational and clinical research into the causes of atherosclerosis and related vascular disease, and how these may affect the …Join the 91st EAS Congress in Mannheim, Germany, from May 21 to 24, 2023, to explore the latest research and clinical guidelines on atherosclerosis and …SAMS: Statin-Associated Muscle Symptoms. In 2015, the European Atherosclerosis Society (EAS) Consensus Panel published a key statement focused on statin-associated muscle symptoms (SAMS). 1 This paper provided important information to assist clinicians in the assessment and management of SAMS in their routine practice, and, uniquely, …Featured Open Lecture: Novembe; On-demand webinar: Beyond targeting LDL ; Certificate of Excellence in Lipidology; On-demand webinar: How to optimize CVD pNov 26, 2021 · European atherosclerosis society/European society of vascular medicine joint statement: lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. Eur. J. Vasc. Med. 8 November 2021; ( Published simultaneously in Atherosclerosis and Vasa ) Nov 10, 2021 · and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel, Eur. Heart J. 38 (2017) 2459–2472. Table 1 Key recommendations for managing peripheral arterial disease (PAD): the European Atherosclerosis Society/European Society of Vascular Medicine Task Force. Recommendation 1. 28 European Atherosclerosis Society, Gothenburg, Sweden. 29 Department of Medicine, Columbia University College of Physicians and Surgeons, New York, USA. 30 National Institute for Health and Medical Research (INSERM), and University of Pierre and Marie Curie-Paris 6, Pitié Salpêtrière, Paris, France. PMID: 29718253 …Aims: The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and, second, to advise on screening for elevated plasma Lp(a), on desirable levels, and on therapeutic strategies. Methods and results: The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease …Dec 31, 2023 · The European Atherosclerosis Journal is an official journal of SITeCS (Italian Society for Experimental and Clinical Therapeutics). The European Atherosclerosis Journal is a new international, peer-reviewed, fully open access, four-monthly journal covering all topics within atherosclerosis and cardiovascular disease areas.The Journal aims to ... The tutorial builds on earlier work done by the European Atherosclerosis Society, addressing the important role of diet and lifestyle which form the basis for dyslipidaemia treatment and CVD prevention. The tutorial includes chapters on CVD risk factors, diet and lifestyle interventions, the role of dietary fats, dietary fibres, foods with ...Based on evidence from large-scale population studies and registries and on consensus of expert opinions, the European Atherosclerosis Society/European Federation of Clinical Chemistry and Laboratory Medicine (EAS/EFLM) joint consensus statement proposes recommendations on (i) situations when fasting is not required for a …Atherosclerosis brings together from all sources papers concerned with research and investigation on atherosclerosis, its complications, and related diseases, …Memo. On behalf of the European Atherosclerosis Society (EAS) and the German societies DACH, DGFF and DGAF we are proud to invite you to participate in the 91st EAS Congress in the city of Mannheim. Mannheim is conveniently located in southern Germany with close access to Frankfurt and is home to inventions such as the …In 2015, the European Atherosclerosis Society (EAS) Consensus Panel published a key statement focused on statin-associated muscle symptoms (SAMS). 1 This paper provided important information to assist clinicians in the assessment and management of SAMS in their routine practice, and, uniquely, appraised what is known to date regarding the …European Atherosclerosis Society, Mässans Gata 10, SE-412 51 Gothenburg, Sweden; 21. Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of ...Nov 26, 2021 · European atherosclerosis society/European society of vascular medicine joint statement: lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. Eur. J. Vasc. Med. 8 November 2021; ( Published simultaneously in Atherosclerosis and Vasa ) Aug 31, 2019 · That’s one of the main messages of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Guidelines on dyslipidaemias published online today in European Heart Journal, (1) and on the ESC website. (2) Cardiovascular disease (CVD) is responsible for more than four million deaths in Europe each year. Aug 31, 2019 · That’s one of the main messages of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Guidelines on dyslipidaemias published online today in European Heart Journal, (1) and on the ESC website. (2) Cardiovascular disease (CVD) is responsible for more than four million deaths in Europe each year. Michal Vrablik, Czech Republic, on the new ESC/EAS guidelines on management of dyslipidaemias. Prof. Ulf Landmesser, Germany, on the importance of the guidelines for clinical practice. Michal Vrablik, Czech Republic, comments on the publication. European Atherosclerosis Society. Första Långgatan 4A. 413 03 Göteborg. Sweden. +46 (0) 31 760 24 27. Based on evidence from large-scale population studies and registries and on consensus of expert opinions, the European Atherosclerosis Society/European Federation of Clinical Chemistry and Laboratory Medicine (EAS/EFLM) joint consensus statement proposes recommendations on (i) situations when fasting is not required for a …28 European Atherosclerosis Society, Gothenburg, Sweden. 29 Department of Medicine, Columbia University College of Physicians and Surgeons, New York, USA. 30 National Institute for Health and Medical Research (INSERM), and University of Pierre and Marie Curie-Paris 6, Pitié Salpêtrière, Paris, France.28 European Atherosclerosis Society, Gothenburg, Sweden. 29 Department of Medicine, Columbia University College of Physicians and Surgeons, New York, USA. 30 National Institute for Health and Medical Research (INSERM), and University of Pierre and Marie Curie-Paris 6, Pitié Salpêtrière, Paris, France. PMID: 29718253 … The official journal of the Society is Atherosclerosis. It is published monthly and is a widely read, widely cited, international publication with an Impact Factor of 6.847. Atherosclerosis brings together from all sources papers concerned with research and investigation on atherosclerosis, its complications, and related diseases, including ... 26 European Atherosclerosis Society, Mässans Gata 10, Gothenburg SE-412 51, Sweden. 27 Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano and IRCCS MultiMedica, Via Festa del Perdono 7, Milan 20122, Italy.Introduction. Three years after the 2016 Guidelines for the management of dyslipidaemia and cardiovascular prevention, the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) released a new guideline document with substantial changes regarding the assessment of cardiovascular risk and treatments. 1–3 … On behalf of the European Atherosclerosis Society (EAS) and the German societies DACH, DGFF and DGAF we are proud to invite you to participate in the 91st EAS Congress in the city of Mannheim. Mannheim is conveniently located in southern Germany with close access to Frankfurt and is home to inventions such as the automobile, bicycle and tractor. Aims: The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD). Methods and results: Of the theoretical estimated prevalence of 1/500 for …
The tutorial builds on earlier work done by the European Atherosclerosis Society, addressing the important role of diet and lifestyle which form the basis for dyslipidaemia treatment and CVD prevention. The tutorial includes chapters on CVD risk factors, diet and lifestyle interventions, the role of dietary fats, dietary fibres, foods with .... 505 central food hall
To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. Join the 92nd EAS Congress in Lyon, the capital of the Gauls, to explore the latest research on the causes and treatment of atherosclerosis and related vascular disease. The congress will offer in-person and virtual attendance, high-level interdisciplinary exchange, and Young Investigator Fellowships. Aug 31, 2019 · That’s one of the main messages of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Guidelines on dyslipidaemias published online today in European Heart Journal, (1) and on the ESC website. (2) Cardiovascular disease (CVD) is responsible for more than four million deaths in Europe each year. This new joint statement from the European Atherosclerosis Society (EAS) and European Society of Vascular Medicine (ESVM) is timely [10]. The mission is two-fold; to update the evidence for two of the major modifiable cardiovascular risk factors - dyslipidaemia and thrombotic factors - and by doing so, improve awareness and …The 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines for the management of dyslipidaemias state that ‘Lp(a) measurement should be considered at least once in each adult person’s lifetime …’. 1 Recently, a similar proposal has been made by the Canadian Cardiovascular Society 2 …A grant (up to 400 €) towards travel & accommodation at Congress. The Fellowships are awarded at the discretion of the organisers. If you have questions regarding your submission, please email [email protected] and …European Atherosclerosis Society | 3,571 followers on LinkedIn. Advancing and exchanging knowledge of the causes, natural history, treatments and prevention of atherosclerotic disease. | For 60 ...This article provides an overview of the European Atherosclerosis Society (EAS) FH Studies Collaboration (FHSC) global consortium and registry, an observational study registered on clinicaltrials.gov (ID: NCT04272697), which is broadly addressing the global burden of FH.Given recent insights into the heterogeneity of genetic defects and clinical phenotype of HoFH, and the availability of new therapeutic options, this Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) critically reviewed available data with the aim of providing clinical guidance for the …To improve risk assessment, imaging techniques are recommended to detect asymptomatic atherosclerosis in individuals at intermediate risk in the 2012 European Society of Cardiology (ESC) Guidelines for Cardiovascular Prevention. 25 Although subjects with FH on average are at much higher risk, risk within FH is sufficiently variable that ...Jan 1, 2020 · No abstract available. Keywords: Guidelines; apolipoprotein B; cholesterol; dyslipidaemias; familial hypercholesterolaemia; high-density lipoproteins; lipoprotein ... This Joint Task Force from the European Atherosclerosis Society and the European Society of Vascular Medicine has updated evidence on the management on dyslipidaemia and thrombotic factors in patients with PAD. Guidelines recommend a low-density lipoprotein cholesterol (LDLC) goal of more than 50% reduction from baseline …Aug 18, 2022 · Abstract. This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, provides clinical guidance for testing and treating elevated Lp(a) levels, and considers its inclusion in global risk estimation. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Download . European Atherosclerosis Society Första Långgatan 4A 413 03 Göteborg Sweden. Phone: +46 (0) 31 760 24 27.In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. One of the novelties of this statement is a new risk calculator showing how Lp(a) influences ...Advancing and exchanging knowledge of the causes, natural history, treatments and prevention of atherosclerotic disease.EAS 2025 – European Atherosclerosis Society. Congress Dates: May 3 – 7, 2025. Congress Venue: Glasgow, United Kingdom . About the Congress: During the meeting we will explore the latest developments in basic, translational and clinical research into the causes of atherosclerosis and related vascular disease, and how these may affect the …Aims: The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD). Methods and results: Of the theoretical estimated prevalence of 1/500 for ….